Basta Pawel, Mach Pawel, Pitynski Kazimierz, Bednarek Wieslawa, Klimek Marek, Zietek Jerzy, Zajac Krzysztof, Wicherek Lukasz
Department of Gynecology and Oncology, Jagiellonian University, 23 Kopernika Str, 31- 501 Krakow, Poland.
Neuro Endocrinol Lett. 2009 Mar;30(1):91-8.
HLA-G is an antigen whose participation in the regulation of the immune system is well documented. The aim of the present study has therefore been to evaluate the sHLA-G blood serum concentrations levels in both women with ovarian endometriosis and women with uterine leiomyomas.
In our study, the soluble HLA-G concentration level was evaluated in the blood serum samples obtained from 98 women who underwent laparotomies or laparoscopies due to either ovarian endometriosis or leiomyomatous uterus. The control group consisted of 42 women, including women on whom a diagnostic laparoscopy identified no lesions, and volunteers-healthy women who returned their blood serum samples during menstrual bleeding.
Patients who underwent surgical treatment because of ovarian endometriosis or uterine leiomyoma, as well as patients from the control group, exhibited no sHLA-G blood serum concentration level fluctuations between the proliferative and secretory menstrual cycle phases. The sHLA-G levels were significantly lower in the patients with ovarian endometriosis and in the patients from the control group during the menstrual cycle phase than in those patients with leiomyoma. A similar relation between the sHLA-G levels of the postmenopausal patients suffering from leiomyoma and the control patients was found. In contrast, the postmenopausal women suffering from endometriosis were typified by levels of sHLA-G blood serum concentration comparable to those of the patients with leiomyoma, and the levels were significantly higher than those observed in the blood sera of the postmenopausal patients from the control group.
The soluble HLA-G blood serum level would seem to be a useful marker for evaluating the status of the microenvironment, where the tumor-immune cell and ectopic and eutopic endometrial interactions take place.
HLA - G是一种抗原，其在免疫系统调节中的参与已有充分记录。因此，本研究的目的是评估卵巢子宫内膜异位症患者和子宫肌瘤患者血清中可溶性HLA - G（sHLA - G）的浓度水平。
在我们的研究中，对98名因卵巢子宫内膜异位症或子宫肌瘤接受剖腹手术或腹腔镜手术的女性的血清样本中的可溶性HLA - G浓度水平进行了评估。对照组由42名女性组成，包括诊断性腹腔镜检查未发现病变的女性以及在月经出血期间返回血清样本的健康志愿者。
因卵巢子宫内膜异位症或子宫肌瘤接受手术治疗的患者以及对照组患者在月经周期的增殖期和分泌期之间，血清sHLA - G浓度水平均无波动。在月经周期阶段，卵巢子宫内膜异位症患者和对照组患者的sHLA - G水平显著低于子宫肌瘤患者。绝经后子宫肌瘤患者与对照患者的sHLA - G水平之间也发现了类似关系。相比之下，绝经后子宫内膜异位症女性的血清sHLA - G浓度水平与子宫肌瘤患者相当，且显著高于对照组绝经后患者血清中的水平。
可溶性HLA - G血清水平似乎是评估肿瘤 - 免疫细胞以及异位和在位子宫内膜相互作用发生的微环境状态的有用标志物。
